“…They include reports on characterization of previously unknown bacteriophages having the potential for use in phage therapy [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ], experimental studies with bacteriophages applied to poultry [ 21 , 22 , 23 , 24 , 25 , 26 ], and the use of bacteriophages in experimental phage therapy in mouse [ 27 , 28 , 29 , 30 ] or pig [ 31 ] models. Although promising results were obtained in these studies, and economic analyses have been performed to assess costs and benefits of the use of phage therapy for the control of Salmonella in poultry [ 9 , 32 ], it is evident that the host range of the vast majority of Salmonella phages is restricted to specific strains or serovars. Therefore, characterization of more bacteriophages infecting various Salmonella serovars and creation of large collections of different bacteriophages capable of killing such differential hosts appears to be necessary for the introduction of effective anti- Salmonella phage therapy.…”